期刊
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
卷 319, 期 2, 页码 H456-H467出版社
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajpheart.00235.2020
关键词
mitochondrial-targeted antioxidant; MitoQ; pulse-wave velocity; vascular function; walking capacity
资金
- University of Nebraska at Omaha Graduate Research and Creative Activity grant
- National Aeronautics and Space Administration Nebraska Space Grant [NNX15AI09H]
- University of Nebraska at Omaha University Committee on Research and Creative Activity grant
- NASA [NNX15AI09H, 803467] Funding Source: Federal RePORTER
Peripheral artery disease (PAD) is a manifestation of atherosclerosis in the leg arteries, which causes claudication. This may be in part due to vascular mitochondrial dysfunction and excessive reactive oxygen species (ROS) production. A mitochondrial-targeted antioxidant (MitoQ) has been shown to improve vascular mitochondrial function that, in turn, led to improved vascular function in older adults and animal models. However, the roles of vascular mitochondria in vascular function including endothelial function and arterial stiffness in patients with PAD are unknown; therefore, with the use of acute MitoQ intake, this study examined the roles of vascular mitochondria in endothelial function, arterial stiffness, exercise tolerance, and skeletal muscle function in patients with PAD. Eleven patients with PAD received either MitoQ or placebo in a randomized crossover design. At each visit, blood samples, brachial and popliteal artery flow-mediated dilation (FMD), peripheral and central pulse-wave velocity (PWV), blood pressure (BP), maximal walking capacity, time to claudication (COT), and oxygen utility capacity were measured pre- and-post-MitoQ and placebo. There were significant group by time interactions (P < 0.05) for brachial and popliteal FMD that both increased by Delta 2.6 and Delta 3.3%, respectively. and increases superoxide dismutase (Delta 0.03 U/mL), maximal walking time (Delta 73.8 5), maximal walking distance (Delta 49.3 m), and COT (Delta 44.2 s). There were no changes in resting heart rate, BP, malondialdehyde. total antioxidant capacity, PWV, or oxygen utility capacity (P > 0.05). MitoQ intake may be an effective strategy for targeting the vascular mitochondrial environment, which may be useful for restoring endothelial function, leg pain. and walking time in patients with PAD. NEW & NOTEWORTHY The results of this study reveal for the first lime that acute oral intake of mitochondrial-targeted antioxidant (MitoQ. 80 mg) is effective for improving vascular endothelial function and superoxide dismutase in patients with peripheral artery disease (PAD). Acute MitoQ intake is also effective for improving maximal walking capacity and delaying the onset of claudication in patients with PAD. These findings suggest that the acute oral intake of MitoQ-mediated improvements in vascular mitochondria play a pivotal role for improving endothelial function, the redox environment, and skeletal muscle performance in PAD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据